Compare J B Hunt Transport Services Inc (JBHT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Mesoblast Limited — how do they compare? J B Hunt Transport Services Inc trades at $275.32 (market cap $24.92B), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: J B Hunt Transport Services Inc is far larger — about 11.3× Mesoblast Limited's market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| JBHT | MESO | |
|---|---|---|
Market Cap | $24.92B | $2.21B |
Sector | Industrials | Technology |
52-Week High | $298.41 | $20.96 |
52-Week Low | $130.65 | $12.88 |
Enterprise Value | $26.06B | $2.21B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT stock trades at $266.14, down 0.89% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue trends show stabilization after a decline from 2022 peaks, while profitability metrics like ROE at 18.45% and net margin at 5.31% reflect efficient operations. Recent news highlights the company's 65th anniversary and partnerships to enhance freight technology.
The outlook is positive with a consensus price target of $299.82, implying 12.6% upside, supported by analyst buy ratings (57.78%). Risks include economic sensitivity impacting freight demand and competitive pressures. Earnings execution and intermodal demand recovery are key catalysts for stock appreciation.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
